Elzi Luigia, Schlegel Matthias, Weber Rainer, Hirschel Bernard, Cavassini Matthias, Schmid Patrick, Bernasconi Enos, Rickenbach Martin, Furrer Hansjakob
University Hospital Basel, Switzerland.
Clin Infect Dis. 2007 Jan 1;44(1):94-102. doi: 10.1086/510080. Epub 2006 Nov 28.
Tuberculin skin testing (TST) and preventive treatment of tuberculosis (TB) are recommended for all persons with human immunodeficiency virus (HIV) infection. We aimed to assess the effect of TST and preventive treatment of TB on the incidence of TB in the era of combination antiretroviral therapy in an area with low rates of TB transmission.
We calculated the incidence of TB among participants who entered the Swiss HIV Cohort Study after 1995, and we studied the associations of TST results, epidemiological and laboratory markers, preventive TB treatment, and combination antiretroviral therapy with TB incidence.
Of 6160 participants, 142 (2.3%) had a history of TB at study entry, and 56 (0.91%) developed TB during a total follow-up period of 25,462 person-years, corresponding to an incidence of 0.22 cases per 100 person-years. TST was performed for 69% of patients; 9.4% of patients tested had positive results (induration > or = 5 mm in diameter). Among patients with positive TST results, TB incidence was 1.6 cases per 100 person-years if preventive treatment was withheld, but none of the 193 patients who received preventive treatment developed TB. Positive TST results (adjusted hazard ratio [HR], 25; 95% confidence interval [CI], 11-57), missing TST results (HR, 12; 95% CI, 4.8-20), origin from sub-Saharan Africa (HR, 5.8; 95% CI, 2.7-12.5), low CD4+ cell counts, and high plasma HIV RNA levels were associated with an increased risk of TB, whereas the risk was reduced among persons receiving combination antiretroviral therapy (HR, 0.44; 95% CI, 0.2-0.8).
Screening for latent TB using TST and administering preventive treatment for patients with positive TST results is an efficacious strategy to reduce TB incidence in areas with low rates of TB transmission. Combination antiretroviral therapy reduces the incidence of TB.
对于所有感染人类免疫缺陷病毒(HIV)的人,建议进行结核菌素皮肤试验(TST)和结核病(TB)预防性治疗。我们旨在评估在结核病传播率较低地区的联合抗逆转录病毒治疗时代,TST和TB预防性治疗对TB发病率的影响。
我们计算了1995年后进入瑞士HIV队列研究的参与者中的TB发病率,并研究了TST结果、流行病学和实验室指标、TB预防性治疗以及联合抗逆转录病毒治疗与TB发病率之间的关联。
在6160名参与者中,142人(2.3%)在研究开始时有TB病史,56人(0.91%)在总共25462人年的随访期内发生了TB,发病率为每100人年0.22例。69%的患者进行了TST;检测的患者中有9.4%结果呈阳性(硬结直径≥5毫米)。在TST结果呈阳性的患者中,如果不进行预防性治疗,TB发病率为每100人年1.6例,但接受预防性治疗的193名患者中无一人发生TB。TST结果呈阳性(调整后的风险比[HR]为25;95%置信区间[CI]为11 - 57)、未进行TST(HR为12;95%CI为4.8 - 20)、来自撒哈拉以南非洲(HR为5.8;95%CI为2.7 - 12.5)、CD4+细胞计数低以及血浆HIV RNA水平高与TB风险增加相关,而接受联合抗逆转录病毒治疗的人群风险降低(HR为0.44;95%CI为0.2 - 0.8)。
使用TST筛查潜伏性TB并对TST结果呈阳性的患者进行预防性治疗是在TB传播率较低地区降低TB发病率的有效策略。联合抗逆转录病毒治疗可降低TB发病率。